NYSEAMERICAN:SYN - Synthetic Biologics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.22 -0.01 (-4.35 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$0.22
Today's Range$0.21 - $0.23
52-Week Range$0.19 - $1.05
Volume427,700 shs
Average Volume738,688 shs
Market Capitalization$49.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.3
Synthetic Biologics logoSynthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms, and the emergence of antimicrobial resistance; and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company's preclinical products include an oral formulation of the enzyme intestinal alkaline phosphatase to treat local GI disorders and systemic diseases; monoclonal antibody therapies for the prevention and treatment of pertussis; and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:SYN
CUSIPN/A
Phone+1-734-3327800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets53.56%

Miscellaneous

EmployeesN/A
Outstanding Shares128,570,000

Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics Inc (NYSEAMERICAN:SYN) posted its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.03. View Synthetic Biologics' Earnings History.

Are investors shorting Synthetic Biologics?

Synthetic Biologics saw a decline in short interest in the month of May. As of May 31st, there was short interest totalling 3,829,755 shares, a decline of 4.1% from the May 15th total of 3,992,335 shares. Based on an average daily volume of 444,859 shares, the days-to-cover ratio is presently 8.6 days. Approximately 3.3% of the shares of the stock are sold short. View Synthetic Biologics' Current Options Chain.

Who are some of Synthetic Biologics' key competitors?

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the folowing people:
  • Mr. Steven A. Shallcross, Interim CEO, CFO, Sec., Treasurer & Sec. (Age 57)
  • Dr. Joseph A. Sliman, Chief Medical Officer (Age 45)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Michael Kaleko M.D., Ph.D., Sr. VP of R&D
  • Dr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing

Has Synthetic Biologics been receiving favorable news coverage?

Press coverage about SYN stock has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Synthetic Biologics earned a media sentiment score of 0.14 on Accern's scale. They also gave news articles about the company an impact score of 45.71 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Synthetic Biologics' major shareholders?

Synthetic Biologics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Blair William & Co. IL (1.54%) and Millennium Management LLC (0.37%). View Institutional Ownership Trends for Synthetic Biologics.

Which major investors are selling Synthetic Biologics stock?

SYN stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Synthetic Biologics.

Which major investors are buying Synthetic Biologics stock?

SYN stock was purchased by a variety of institutional investors in the last quarter, including Blair William & Co. IL. View Insider Buying and Selling for Synthetic Biologics.

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.22.

How big of a company is Synthetic Biologics?

Synthetic Biologics has a market capitalization of $49.23 million.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800.


MarketBeat Community Rating for Synthetic Biologics (SYN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  247 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe SYN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.